Comparative assessment of <scp>PDE</scp> 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis
Coral González‐García(Universidad a Distancia de Madrid), Sara Ballester(Instituto de Salud Carlos III), Carmen Gil(Instituto de Salud Carlos III), Beatriz Bravo(Instituto de Salud Carlos III), Alicia Ballester(Instituto de Salud Carlos III), R Gómez‐Pérez(Instituto de Salud Carlos III), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Miriam Redondo(Instituto de Química Médica), César Eguiluz(Instituto de Salud Carlos III)
Cited by 52
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293